Novavax (NVAX) Expected to Announce Earnings on Thursday

Novavax (NASDAQ:NVAX) is expected to be releasing its earnings data before the market opens on Thursday, February 27th. Analysts expect Novavax to post earnings of ($0.75) per share and revenue of $85.48 million for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.

Novavax Stock Performance

Novavax stock opened at $7.17 on Wednesday. Novavax has a fifty-two week low of $3.81 and a fifty-two week high of $23.86. The stock has a market cap of $1.15 billion, a PE ratio of -3.17, a price-to-earnings-growth ratio of 2.85 and a beta of 2.14. The firm’s 50-day simple moving average is $8.62 and its 200 day simple moving average is $10.07.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $19.00 price target on shares of Novavax in a report on Tuesday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, Novavax has an average rating of “Hold” and an average target price of $17.83.

Insider Buying and Selling at Novavax

In other Novavax news, Director Rachel K. King sold 4,150 shares of the business’s stock in a transaction dated Friday, December 13th. The shares were sold at an average price of $9.02, for a total value of $37,433.00. Following the transaction, the director now directly owns 14,770 shares in the company, valued at $133,225.40. The trade was a 21.93 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director James F. Young sold 5,400 shares of the business’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $8.00, for a total transaction of $43,200.00. Following the completion of the sale, the director now directly owns 51,760 shares in the company, valued at approximately $414,080. This trade represents a 9.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 14,150 shares of company stock worth $119,641 over the last three months. 1.00% of the stock is currently owned by insiders.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.